EVIDENCE LIBRARY

How Did an Akathisia Case Separate Tolerability From Psychotic Symptoms?

Control of an adverse movement effect can make continued treatment possible while leaving a medication’s direct effect on psychosis a separate question. A 2018 case report described this sequence during clozapine treatment.

What the patient experienced

The woman had previously stopped several antipsychotics because of akathisia. Clozapine initially reduced psychotic symptoms, but restlessness and an urge to move returned as its dose increased. The authors used symptom history and examination to distinguish akathisia from restless legs syndrome and recorded Barnes Akathisia Scale scores.

How treatment and outcomes evolved

Additional benzodiazepines and a clozapine increase were accompanied by worsening akathisia. Gabapentin enacarbil was subsequently added, after which the reported akathisia score fell to zero. Clozapine could then be increased further without reported recurrence, and psychotic symptoms improved.

Which inference needs care?

The authors proposed an indirect benefit: better tolerability facilitated continued clozapine treatment. The sequence supplies limited ability to isolate the independent contribution of each medication to later psychotic improvement. It also provides no controlled estimate of gabapentin enacarbil’s effectiveness for other patients with akathisia. For readers reviewing a medication course, adverse-effect ratings, target psychiatric symptoms, dose changes, and functional outcomes should remain separate on the timeline. An improvement in one domain may enable another treatment decision. Whether that decision produced a subsequent benefit requires consideration of the complete course and the limitations of a single case.

Source

Read the full scientific paper. DOI 10.9758/cpn.2018.16.3.346.